Six Biotech Firms Race to Cure Common Liver Disease

A wave of hope is building for millions living with a serious liver disease that had no approved treatments until two years ago.

Metabolic dysfunction-associated steatohepatitis, or MASH, causes dangerous inflammation and scarring in the liver. It's become one of the hottest areas in drug development, especially after regulators approved the first treatment in 2024.

Now six biotech companies are pushing forward with promising new therapies, each taking a different approach to tackle the disease. The excitement is real. In 2025 alone, pharmaceutical giants GSK, Roche, and Novo Nordisk invested billions of dollars in deals with MASH-focused companies.

Altimmune is leading with pemvidutide, a drug that attacks liver fat, inflammation, and scarring while also helping patients lose weight. The FDA recently granted it Breakthrough Therapy status after a trial showed significant improvements in liver health. The company raised $300 million this year to fund final-stage testing.

Arrowhead Pharmaceuticals is taking a genetic approach with three different therapies that silence specific genes driving liver damage. Their candidate ARO-INHBE recently showed impressive reductions in liver fat, both alone and when combined with diabetes medications.

Galectin Therapeutics developed belapectin, which targets the scarring process directly. After showing promise in reducing dangerous esophageal bleeding complications, the company is now testing whether it can prevent liver-related deaths.

Inventiva's lanifibranor works on three different cellular pathways at once to reduce fat buildup and inflammation. Early results showed 75% of patients experienced significant improvement in liver health.

The Ripple Effect

The progress these companies are making reaches far beyond lab results. MASH affects up to 6.5% of adults worldwide and is closely linked to obesity and diabetes, two conditions that have reached epidemic levels.

For years, doctors could only tell patients to lose weight and hope their livers would improve. Now they're seeing multiple potential treatments emerge, each offering different benefits and working through unique mechanisms.

The competition among these companies is actually accelerating progress. As each one publishes promising results, others learn and adapt their approaches. Patients in clinical trials are already experiencing real improvements in liver health, weight loss, and overall wellbeing.

Several of these therapies could reach the market within the next few years. That means millions of people who currently have no good options will soon have choices.

The race to develop better MASH treatments proves that when science, investment, and human need align, breakthrough solutions emerge faster than anyone expected.